Impact of COPD and emphysema on survival of patients with lung cancer: A meta-analysis of observational studies

Respirology

Volumn 21, Issue 2, 2016, Pages 269-279

  Gao, Yong Hua ^a   Guan, Wei Jie ^a   Liu, Qi ^a   Wang, Hua Qi ^a   Zhu, Ya Nan ^b   Chen, Rong Chang ^a   Zhang, Guo Jun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

chronic obstructive pulmonary disease; lung cancer; meta analysis; prognosis

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; EMPHYSEMA; HAZARD RATIO; HUMAN; LUNG CANCER; META ANALYSIS; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; DISEASE MANAGEMENT; LUNG; LUNG NEOPLASMS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA;

COMORBIDITY; DISEASE MANAGEMENT; DISEASE-FREE SURVIVAL; EARLY DIAGNOSIS; HUMANS; LUNG; LUNG NEOPLASMS; NEOPLASM STAGING; OBSERVATIONAL STUDIES AS TOPIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA;

EID: 84955343011     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12661     Document Type: Review

References (51)

1. Janssen-Heijnen ML, Schipper RM, Razenberg PP, Crommelin MA, Coebergh JW,. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 1998; 21: 105-113.
2. de Cos JS, Miravet L, Abal J, Núñez A, Muñoz FJ, García L, Castañar AM, Montero MA, Hernández J, Alonso MA,. Lung cancer survival in Spain and prognostic factors: a prospective, multiregional study. Lung Cancer 2008; 59: 246-254.
3. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P,. Impact of comorbidity on lung cancer survival. Int. J. Cancer 2003; 103: 792-802.
4. Luchtenborg M, Jakobsen E, Krasnik M, Linklater KM, Mellemgaard A, Møller H,. The effect of comorbidity on stage-specific survival in resected non-small cell lung cancer patients. Eur. J. Cancer 2012; 48: 3386-3395.
5. Iachina M, Jakobsen E, Moller H, Lüchtenborg M, Mellemgaard A, Krasnik M, Green A,. The effect of different comorbidities on survival of non-small cells lung cancer patients. Lung 2015; 193: 291-297.
6. Loganathan RS, Stover DE, Shi W, Venkatraman E,. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest 2006; 129: 1305-1312.
7. Congleton J, Muers MF,. The incidence of airflow obstruction in bronchial carcinoma, its relation to breathlessness, and response to bronchodilator therapy. Respir. Med. 1995; 89: 291-296.
8. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD,. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur. Respir. J. 2009; 34: 380-386.
9. Smith BM, Pinto L, Ezer N, Sverzellati N, Muro S, Schwartzman K,. Emphysema detected on computed tomography and risk of lung cancer: a systematic review and meta-analysis. Lung Cancer 2012; 77: 58-63.
10. Wang H, Yang L, Zou L, Huang D, Guo Y, Pan M, Tan Y, Zhong H, Ji W, Ran P, et al. Association between chronic obstructive pulmonary disease and lung cancer: a case-control study in Southern Chinese and a meta-analysis. PLoS ONE 2012; 7: e46144.
11. Yang L, Yang X, Ji W, Deng J, Qiu F, Yang R, Fang W, Zhang L, Huang D, Xie C, et al. Effects of a functional variant c.353T>C in snai1 on risk of two contextual diseases. Chronic obstructive pulmonary disease and lung cancer. Am. J. Respir. Crit. Care Med. 2014; 189: 139-148.
12. Turner MC, Chen Y, Krewski D, Calle EE, Thun MJ,. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am. J. Respir. Crit. Care Med. 2007; 176: 285-290.
13. Zhai R, Yu X, Shafer A, Wain JC, Christiani DC,. The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection. Chest 2014; 145: 346-353.
14. Lee SJ, Lee J, Park YS, Lee CH, Lee SM, Yim JJ, Yoo CG, Han SK, Kim YW,. Impact of chronic obstructive pulmonary disease on the mortality of patients with non-small-cell lung cancer. J. Thorac. Oncol. 2014; 9: 812-817.
15. Gullon JA, Suarez I, Medina A, Rubinos G, Fernández R, González I,. Role of emphysema and airway obstruction in prognosis of lung cancer. Lung Cancer 2011; 71: 182-185.
16. Abal Arca J, Parente Lamelas I, Almazan Ortega R, Blanco Pérez J, Toubes Navarro ME, Marcos Velázquez P,. Lung cancer and COPD: a common combination. Arch. Bronconeumol. 2009; 45: 502-507.
17. Bishawi M, Moore W, Bilfinger T,. Severity of emphysema predicts location of lung cancer and 5-y survival of patients with stage I nonesmall cell lung cancer. J. Surg. Res. 2013; 184: 1-5.
18. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR,. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16. doi: 10.1186/1745-6215-8-16.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
20. Kuo CH, Wu CY, Lee KY, Lin SM, Chung FT, Lo YL, Liu CY, Hsiung TC, Yang CT, Wu YC,. Chronic obstructive pulmonary disease in stage I non-small cell lung cancer that underwent anatomic resection: the role of a recurrence promoter. COPD 2014; 11: 407-413.
21. Kumagai S, Marumo S, Yamanashi K, Tokuno J, Ueda Y, Shoji T, Nishimura T, Huang CL, Fukui M,. Prognostic significance of combined pulmonary fibrosis and emphysema in patients with resected non-small-cell lung cancer: a retrospective cohort study. Eur. J. Cardiothorac Surg. 2014; 46: e113-119.
22. Yamamoto S, Tamura T, Matsumura A, Atagi S, Kitaichi M, Kawaguchi T, Hirata K,. Does presence of chronic obstructive pulmonary disease (COPD) influence clinical behavior in patients with early stage nonsmall cell lung cancer (ES-NSCLC)? J. Thorac. Oncol. 2013; 8: S921-922.
23. Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Gomez DR,. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann. Oncol. 2013; 24: 1312-1319.
24. Sekine Y, Suzuki H, Yamada Y, Koh E, Yoshino I,. Severity of chronic obstructive pulmonary disease and its relationship to lung cancer prognosis after surgical resection. Thorac. Cardiovasc. Surg. 2013; 61: 124-130.
25. Mina N, Soubani AO, Cote ML, Suwan T, Wenzlaff AS, Jhajhria S, Samarah H, Schwartz AG,. The relationship between chronic obstructive pulmonary disease and lung cancer in African American patients. Clin. Lung Cancer 2012; 13: 149-156.
26. Usui K, Tanai C, Tanaka Y, Noda H, Ishihara T,. The prevalence of pulmonary fibrosis combined with emphysema in patients with lung cancer. Respirology 2011; 16: 326-331.
27. Kondo R, Yoshida K, Eguchi T, Kobayashi N, Saito G, Hamanaka K, Shiina T, Kurai M,. Clinical features of lung cancer in smokers with light and mild chronic obstructive pulmonary disease: a retrospective analysis of Japanese surgical cases. Eur. J. Cardiothorac Surg. 2011; 40: 1439-1443.
28. Lee SA, Sun JS, Park JH, Park KJ, Lee SS, Choi H, Sheen SS, Chung WY, Lee KS, Park KJ, et al. Emphysema as a risk factor for the outcome of surgical resection of lung cancer. J. Korean Med. Sci. 2010; 25: 1146-1151.
29. Kiri VA, Soriano JB, Visick G, Fabbri L,. Recent trends in lung cancer and its association with COPD: an analysis using the UK GP research database. Prim. Care Respir. J. 2010; 19: 57-61.
30. van de Schans SAM, Janssen-Heijnen MLG, Biesma B, Smeenk FW, van de Poll-Franse LV, Seynaeve C, Coebergh JW,. COPD in cancer patients: higher prevalence in the elderly, a different treatment strategy in case of primary tumours above the diaphragm, and a worse overall survival in the elderly patient. Eur. J. Cancer 2007; 43: 2194-2202.
31. Ueda K, Jinbo M, Li TS, Yagi T, Suga K, Hamano K,. Computed tomography-diagnosed emphysema, not airway obstruction, is associated with the prognostic outcome of early-stage lung cancer. Clin. Cancer Res. 2006; 12: 6730-6736.
32. Dy SM, Sharkey P, Herbert R, Haddad K, Wu AW,. Comorbid illnesses and health care utilization among Medicare beneficiaries with lung cancer. Crit. Rev. Oncol. Hematol 2006; 59: 218-225.
33. Birim O, Kappetein AP, Waleboer M, Puvimanasinghe JP, Eijkemans MJ, Steyerberg EW, Versteegh MI, Bogers AJ,. Long-term survival after non-small cell lung cancer surgery: development and validation of a prognostic model with a preoperative and postoperative mode. J. Thorac. Cardiovasc. Surg. 2006; 132: 491-498.
34. Lopez-Encuentra A, Astudillo J, Cerezal J, Gonzalez-Aragoneses F, Novoa N, Sánchez-Palencia A,. Prognostic value of chronic obstructive pulmonary disease in 2994 cases of lung cancer. Eur. J. Cardiothorac Surg. 2005; 27: 8-13.
35. Sekine Y, Behnia M, Fujisawa T,. Impact of COPD on pulmonary complications and on long-term survival of patients undergoing surgery for NSCLC. Lung Cancer 2002; 37: 95-101.
36. Kurishima K, Satoh H, Ishikawa H, Yamashita YT, Homma T, Ohtsuka M, Sekizawa K,. Lung cancer patients with chronic obstructive pulmonary disease. Oncol. Rep. 2001; 8: 63-65.
37. Jian ZH, Huang JY, Ko PC, Jan SR, Nfor ON, Lung CC, Ku WY, Ho CC, Pan HH, Liaw YP,. Impact of coexisting pulmonary diseases on survival of patients with lung adenocarcinoma: a STROBE-Compliant article. Medicine (Baltimore) 2015; 94: e443.
38. Yoshida Y, Kage H, Murakawa T, Sato Y, Ota S, Fukayama M, Nakajima J,. Worse prognosis for stage IA lung cancer patients with smoking history and more severe chronic obstructive pulmonary disease. Ann. Thorac. Cardiovasc. Surg. 2015; 21: 194-200.
39. Sekine Y, Yamada Y, Chiyo M, Iwata T, Nakajima T, Yasufuku K, Suzuki M, Fujisawa T,. Association of chronic obstructive pulmonary disease and tumor recurrence in patients with stage IA lung cancer after complete resection. Ann. Thorac. Surg. 2007; 84: 946-950.
40. O'Callaghan DS, O'Donnell D, O'Connell F, O'Byrne KJ,. The role of inflammation in the pathogenesis of non-small cell lung cancer. J. Thorac. Oncol. 2010; 5: 2024-2036.
41. Lee G, Walser TC, Dubinett SM,. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr. Opin. Pulm. Med. 2009; 15: 303-307.
42. Cerda S, Weitzman SA,. Influence of oxygen radical injury on DNA methylation. Mutat. Res. 1997; 386: 141-152.
43. Takenaka T, Yano T, Kiyohara C, Miura N, Kouso H, Ohba T, Kometani T, Shoji F, Yoshino I, Maehara Y,. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 2010; 67: 101-107.
44. Demedts IK, Demoor T, Bracke KR, Joos GF, Brusselle GG,. Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respir. Res. 2006; 7: 53. doi: 10.1186/1465-9921-7-53.
45. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM,. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin. Cancer Res. 2005; 11: 3974-3986.
46. Liloglou T, Bediaga NG, Brown BR, Field JK, Davies MP,. Epigenetic biomarkers in lung cancer. Cancer Lett. 2014; 342: 200-212.
47. Qiu W, Baccarelli A, Carey VJ, Boutaoui N, Bacherman H, Klanderman B, Rennard S, Agusti A, Anderson W, Lomas DA, et al. Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. Am. J. Respir. Crit. Care Med. 2012; 185: 373-381.
48. Inal A, Kaplan MA, Kucukoner M, Urakci Z, Kilinc F, Isikdogan A,. Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer? Rev. Port. Pneumol. 2014; 20: 62-68.
49. Takenaka T, Katsura M, Shikada Y, Tsukamoto S, Takeo S,. The impact of cardiovascular comorbidities on the outcome of surgery for non-small-cell lung cancer. Interact. Cardiovasc. Thorac. Surg. 2013; 16: 270-274.
50. Zhang J, Zhou JB, Lin XF, Wang Q, Bai CX, Hong QY,. Prevalence of undiagnosed and undertreated chronic obstructive pulmonary disease in lung cancer population. Respirology 2013; 18: 297-302.
51. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6: doi: 10.1371/journal.pmed1000097.